-transparent.png){kind=logo}
Results of previous studies indicated that insulin at levels comparable to those in humans during hyperinsulinemia decreased ACTH-stimulated cortisol and androstenedione secretion by bovine adrenal fasciculata-reticularis cells in primary culture. In the present studies this inhibitory action was examined further by comparing the effects of insulin on ACTH-stimulated corticosteroid secretion with its effects on 8-(4-chlorophenylthio)-cAMP (cpt-cAMP), forskolin- and [5val]angiotensin II (Ang II)-stimulated corticosteroid secretion. Effects on corticosteroid secretion were correlated with effects on cAMP accumulation and rates of cAMP production. Monolayers were incubated for 24 h in the absence or presence of each agonist alone or in combination with insulin. Insulin (1.7 x 10(-9) or 17.5 x 10(-9) M) caused about a 50% decrease in cortisol and androstenedione secretion in response to ACTH (10(-11) or 10(-8) M). Insulin also decreased ACTH-stimulated aldosterone secretion by cultured glomerulosa cells. Cpt-cAMP (10(-4) or 10(-3) M)-stimulated increases in cortisol and androstenedione secretion were inhibited by insulin, but to a lesser extent than those in response to ACTH. The inhibition of cpt-cAMP-stimulated steroid secretion was not related to increased degradation of the cyclic nucleotide. Increases in cortisol and androstenedione secretion caused by a submaximal concentration (10(-6) M) of forskolin were decreased 50-70% by insulin. In contrast, insulin failed to significantly affect cortisol or androstenedione secretion caused by a maximal concentration (10(-5) M) of forskolin. The secretory responses to Ang II (10(-8) M) were also unaffected by insulin. The effect of insulin to inhibit ACTH-stimulated steroid secretion was accompanied by a reduction in cAMP accumulation as well as an apparent inhibition of adenylate cyclase activation. These data indicate that the effect of insulin to attenuate ACTH-stimulated corticosteroid secretion results from both an inhibition of ACTH-stimulated adenylate cyclase activity and an antagonism of the intracellular actions of cAMP.
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
January 1995,
Endocrine research,
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
November 2000,
Endocrine research,
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
March 1958,
Science (New York, N.Y.),
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
May 2003,
International journal of molecular medicine,
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
March 1989,
The Journal of endocrinology,
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
March 1997,
Inflammation research : official journal of the European Histamine Research Society ... [et al.],
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
March 1997,
Inflammation research : official journal of the European Histamine Research Society ... [et al.],
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
February 2002,
American journal of physiology. Endocrinology and metabolism,
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
May 2010,
Reproductive sciences (Thousand Oaks, Calif.),
N A Klein, and
R N Andersen, and
P R Casson, and
J E Buster, and
R E Kramer
January 1990,
Endocrinology,
